Over 5.8 million people in America are living with Alzheimer’s in 2019. Half of the estimated 5.8 million have never received a diagnosis. An early documented diagnosis, communicated to the patient and caregiver enables early access to care planning services, treatments, and optimizes the ability to build a care team, participate in services and enroll in clinical trials. The inability to find eligible patients at early stages of the disease highly affects the research that can be conducted towards Alzheimer’s disease prevention, treatment, and cure. In 2019, $195 billion have been spent on Alzheimer’s and related dementias through Medicare and Medicaid programs. This price is estimated to rise to $1.1 trillion by 2050.
Under current coverage of the Social Security act only the detection of cognitive impairment is required to have further consideration. The Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019 implements that the detection of cognitive impairment or progression of impairment requires further consideration, along with documentation of the tool and the measures. This policy also requires referral of patient with detected cognitive impairment or potential decline to diagnostic services, specialist, community based services and clinical trials This bill will work to accelerate progress towards prevention strategies, disease modifying treatments, and a cure. It will also improve early detection of Alzheimer’s and result in better care planning and reduce the emotional, financial, and physical burdens.
Your signature will get us one step closer to finding a cure!